Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hepatitis B immune globulin - Emergent BioSolutions

Drug Profile

Hepatitis B immune globulin - Emergent BioSolutions

Alternative Names: HepaGam B; ImmunoGam

Latest Information Update: 04 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cangene Corporation
  • Developer Aptevo Therapeutics; Emergent BioSolutions; Saol Therapeutics
  • Class Antivirals; Immunoglobulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatitis B
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis B

Most Recent Events

  • 04 Jul 2019 Hepatitis B immune globulin is not yet available for Hepatitis B (Prevention of relapse) in Kuwait (IV)
  • 04 Jul 2019 Hepatitis B immune globulin is not yet available for Hepatitis B (Prevention) in Kuwait (IM)
  • 28 Sep 2017 Saol Therapeutics completes the acquisition of Hepatitis B immunoglobulin from Aptevo Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top